• 13 Jul 26

Poolbeg Pharma doses first patient in POLB 001 TOPICAL Clinical Trial

Poolbeg Pharma doses first patient in POLB 001 TOPICAL Clinical Trial

Poolbeg Pharma PLC | POLB | 8.2 -0.16 (0.0%)

    • 26 views

 
Poolbeg Pharma (POLB) has dosed the first patient in its POLB 001 TOPICAL clinical trial, marking the start of clinical execution for its programme targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapies. Interim data remains on track for late summer 2026, while partnering discussions with multiple companies continue to progress.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Vox Markets Video Wrap

Companies: ALUVTYGHHHEADMSISAAFOXTALFARFXCBOXBRCKEYERORSYSCERBKSLIKEDOCSADVTLINVBIGPOLBEGT

Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug

Companies: Poolbeg Pharma PLC

Poolbeg Pharma doses first patient in CRS prevention trial at The Christie

Companies: Poolbeg Pharma PLC

Vox Markets Weekly Wrap

Companies: SKLCTLSDGELCOIGPGBGTTGTATETEPORRTRCSASAIEYESHOEPXENW7LRBWAOMDCCPALMMPALPOLBATG

Poolbeg Pharma doses first patient in TOPICAL clinical trial

Companies: Poolbeg Pharma PLC

Poolbeg Pharma kicks off POLB001 Phase 2a trial with specialist partner

Companies: Poolbeg Pharma PLC

© Research Tree 2026

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top